Please enable JavaScript to continue using this application.

Compare $AKBA vs $PLX | Chartloom

Compare

$AKBA vs $PLX

Akebia Therapeutics Inc · Protalix Biotherapeutics Inc

AKBA

Akebia Therapeutics Inc

PLX

Protalix Biotherapeutics Inc

Compare $AKBA vs $PLX

Comparing Akebia Therapeutics Inc and Protalix Biotherapeutics Inc

AKBAAkebia Therapeutics Inc

PLXProtalix Biotherapeutics Inc

AKBAAkebia Therapeutics Inc

Market cap

$215M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.35x

Rev growth (TTM)

7.5%

YTD performance

-48.3%

52W performance

-71.9%

FCF yield

13.7%

PLXProtalix Biotherapeutics Inc

Market cap

$224M

P/E (TTM)

12.11x

Forward P/E (NTM)

—

Forward P/S (NTM)

3.56x

Rev growth (TTM)

30.1%

YTD performance

59.8%

52W performance

8.2%

FCF yield

3.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AKBA

PLX

Detailed metrics comparison

AKBA

Akebia Therapeutics Inc

PLX

Protalix Biotherapeutics Inc

Market Cap

AKBA$215M

PLX$224M

Enterprise Value

AKBA$252M

PLX$197M

Price

AKBA$0.80

PLX$2.78

P/E Ratio

AKBAN/A

PLX12.11x

P/S Ratio

AKBA0.98x

PLX2.78x

EV/Sales

AKBA1.15x

PLX2.44x

EV/EBITDA

AKBA49.22x

PLX7.37x

P/B Ratio

AKBA9.58x

PLX3.06x

P/FCF Ratio

AKBA7.30x

PLX29.21x

EV/FCF

AKBA8.54x

PLX25.63x

PEG Ratio

AKBAN/A

PLX0.06x

Forward P/E (NTM)

AKBAN/A

PLXN/A

Forward P/S (NTM)

AKBA1.35x

PLX3.56x

Revenue (TTM)

AKBA$219M

PLX$81M

Revenue Growth (YoY)

AKBA7.5%

PLX30.1%

Forward Rev Growth

AKBA-33.0%

PLX-19.1%

Gross Margin (TTM)

AKBA81.5%

PLX69.2%

Operating Margin (TTM)

AKBA0.0%

PLX28.9%

EBITDA Margin (TTM)

AKBA-1.9%

PLX30.8%

Net Margin (TTM)

AKBA-13.5%

PLX23.5%

FCF Margin (TTM)

AKBA13.4%

PLX9.5%

Net Income (TTM)

AKBA$-30M

PLX$19M

FCF (TTM)

AKBA$29M

PLX$8M

EPS (TTM)

AKBA-$0.11

PLX$0.23

ROE (TTM)

AKBA-9374.0%

PLX31.6%

ROA (TTM)

AKBA-817.0%

PLX20.1%

ROIC (TTM)

AKBA-1321.0%

PLX31.6%

Cash

AKBA$156M

PLX$27M

Debt

AKBA$192M

PLX$0

Net Cash/Debt

AKBA$-37M

PLX$27M

Current Ratio (TTM)

AKBA1.43x

PLX2.94x

Quick Ratio (TTM)

AKBA1.31x

PLX1.91x

Debt/Equity (TTM)

AKBA7.69x

PLX0.00x

Debt/Assets (TTM)

AKBA0.0%

PLX0.0%

Interest Coverage (TTM)

AKBAN/A

PLXN/A

Net Debt/EBITDA (TTM)

AKBA0.00x

PLX0.00x

Beta

AKBA0.20

PLX-0.05

52W Performance

AKBA-71.9%

PLX8.2%

YTD Performance

AKBA-48.3%

PLX59.8%

% from 52W High

AKBA-75.0%

PLX-12.9%

% from 52W Low

AKBA0.0%

PLX73.7%

Asset Turnover (TTM)

AKBA0.60x

PLX0.85x

FCF Yield (TTM)

AKBA13.7%

PLX3.4%

Earnings Yield (TTM)

AKBA-13.8%

PLX8.5%

Dividend Yield (TTM)

AKBAN/A

PLXN/A

Rule of 40

AKBA21.0

PLX39.7

EV/GP/RG

AKBAN/A

PLXN/A

Ticker research

View AKBA research View PLX research

Metric	AKBA Akebia Therapeutics Inc	PLX Protalix Biotherapeutics Inc
Market & Valuation
Market Cap	$215M	$224M
Enterprise Value	$252M	$197M
Price	$0.80	$2.78
P/E Ratio	N/A	12.11x
P/S Ratio	0.98x	2.78x
EV/Sales	1.15x	2.44x
EV/EBITDA	49.22x	7.37x
P/B Ratio	9.58x	3.06x
P/FCF Ratio	7.30x	29.21x
EV/FCF	8.54x	25.63x
PEG Ratio	N/A	0.06x
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.35x	3.56x
Revenue & Growth
Revenue (TTM)	$219M	$81M
Revenue Growth (YoY)	7.5%	30.1%
Forward Rev Growth	-33.0%	-19.1%
Profitability
Gross Margin (TTM)	81.5%	69.2%
Operating Margin (TTM)	0.0%	28.9%
EBITDA Margin (TTM)	-1.9%	30.8%
Net Margin (TTM)	-13.5%	23.5%
FCF Margin (TTM)	13.4%	9.5%
Net Income (TTM)	$-30M	$19M
FCF (TTM)	$29M	$8M
EPS (TTM)	-$0.11	$0.23
ROE (TTM)	-9374.0%	31.6%
ROA (TTM)	-817.0%	20.1%
ROIC (TTM)	-1321.0%	31.6%
Financial Health
Cash	$156M	$27M
Debt	$192M	$0
Net Cash/Debt	$-37M	$27M
Current Ratio (TTM)	1.43x	2.94x
Quick Ratio (TTM)	1.31x	1.91x
Debt/Equity (TTM)	7.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.20	-0.05
52W Performance	-71.9%	8.2%
YTD Performance	-48.3%	59.8%
% from 52W High	-75.0%	-12.9%
% from 52W Low	0.0%	73.7%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.85x
FCF Yield (TTM)	13.7%	3.4%
Earnings Yield (TTM)	-13.8%	8.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	21.0	39.7
EV/GP/RG	N/A	N/A
Ticker research	View AKBA research	View PLX research

Valuation

P/E Ratio

PLX

12.11x

P/S Ratio

AKBA

0.98x

PLX

2.78x

EV/FCF

AKBA

8.54x

PLX

25.63x

Growth & revenue

Revenue Growth TTM

PLX

30.1%

AKBA

7.5%

Forward Revenue Growth

PLX

-19.1%

AKBA

-33.0%

Profitability & performance

Gross Margin

AKBA

81.5%

PLX

69.2%

ROE

PLX

31.6%

AKBA

-9374.0%

FCF Yield %

AKBA

13.7%

PLX

3.4%

52-Week Performance

PLX

8.2%

AKBA

-71.9%

Detailed metrics comparison

AKBA

Akebia Therapeutics Inc

PLX

Protalix Biotherapeutics Inc

Market Cap

AKBA$215M

PLX$224M

Enterprise Value

AKBA$252M

PLX$197M

Price

AKBA$0.80

PLX$2.78

P/E Ratio

AKBAN/A

PLX12.11x

P/S Ratio

AKBA0.98x

PLX2.78x

EV/Sales

AKBA1.15x

PLX2.44x

EV/EBITDA

AKBA49.22x

PLX7.37x

P/B Ratio

AKBA9.58x

PLX3.06x

P/FCF Ratio

AKBA7.30x

PLX29.21x

EV/FCF

AKBA8.54x

PLX25.63x

PEG Ratio

AKBAN/A

PLX0.06x

Forward P/E (NTM)

AKBAN/A

PLXN/A

Forward P/S (NTM)

AKBA1.35x

PLX3.56x

Revenue (TTM)

AKBA$219M

PLX$81M

Revenue Growth (YoY)

AKBA7.5%

PLX30.1%

Forward Rev Growth

AKBA-33.0%

PLX-19.1%

Gross Margin (TTM)

AKBA81.5%

PLX69.2%

Operating Margin (TTM)

AKBA0.0%

PLX28.9%

EBITDA Margin (TTM)

AKBA-1.9%

PLX30.8%

Net Margin (TTM)

AKBA-13.5%

PLX23.5%

FCF Margin (TTM)

AKBA13.4%

PLX9.5%

Net Income (TTM)

AKBA$-30M

PLX$19M

FCF (TTM)

AKBA$29M

PLX$8M

EPS (TTM)

AKBA-$0.11

PLX$0.23

ROE (TTM)

AKBA-9374.0%

PLX31.6%

ROA (TTM)

AKBA-817.0%

PLX20.1%

ROIC (TTM)

AKBA-1321.0%

PLX31.6%

Cash

AKBA$156M

PLX$27M

Debt

AKBA$192M

PLX$0

Net Cash/Debt

AKBA$-37M

PLX$27M

Current Ratio (TTM)

AKBA1.43x

PLX2.94x

Quick Ratio (TTM)

AKBA1.31x

PLX1.91x

Debt/Equity (TTM)

AKBA7.69x

PLX0.00x

Debt/Assets (TTM)

AKBA0.0%

PLX0.0%

Interest Coverage (TTM)

AKBAN/A

PLXN/A

Net Debt/EBITDA (TTM)

AKBA0.00x

PLX0.00x

Beta

AKBA0.20

PLX-0.05

52W Performance

AKBA-71.9%

PLX8.2%

YTD Performance

AKBA-48.3%

PLX59.8%

% from 52W High

AKBA-75.0%

PLX-12.9%

% from 52W Low

AKBA0.0%

PLX73.7%

Asset Turnover (TTM)

AKBA0.60x

PLX0.85x

FCF Yield (TTM)

AKBA13.7%

PLX3.4%

Earnings Yield (TTM)

AKBA-13.8%

PLX8.5%

Dividend Yield (TTM)

AKBAN/A

PLXN/A

Rule of 40

AKBA21.0

PLX39.7

EV/GP/RG

AKBAN/A

PLXN/A

Ticker research

View AKBA research View PLX research

Metric	AKBA Akebia Therapeutics Inc	PLX Protalix Biotherapeutics Inc
Market & Valuation
Market Cap	$215M	$224M
Enterprise Value	$252M	$197M
Price	$0.80	$2.78
P/E Ratio	N/A	12.11x
P/S Ratio	0.98x	2.78x
EV/Sales	1.15x	2.44x
EV/EBITDA	49.22x	7.37x
P/B Ratio	9.58x	3.06x
P/FCF Ratio	7.30x	29.21x
EV/FCF	8.54x	25.63x
PEG Ratio	N/A	0.06x
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.35x	3.56x
Revenue & Growth
Revenue (TTM)	$219M	$81M
Revenue Growth (YoY)	7.5%	30.1%
Forward Rev Growth	-33.0%	-19.1%
Profitability
Gross Margin (TTM)	81.5%	69.2%
Operating Margin (TTM)	0.0%	28.9%
EBITDA Margin (TTM)	-1.9%	30.8%
Net Margin (TTM)	-13.5%	23.5%
FCF Margin (TTM)	13.4%	9.5%
Net Income (TTM)	$-30M	$19M
FCF (TTM)	$29M	$8M
EPS (TTM)	-$0.11	$0.23
ROE (TTM)	-9374.0%	31.6%
ROA (TTM)	-817.0%	20.1%
ROIC (TTM)	-1321.0%	31.6%
Financial Health
Cash	$156M	$27M
Debt	$192M	$0
Net Cash/Debt	$-37M	$27M
Current Ratio (TTM)	1.43x	2.94x
Quick Ratio (TTM)	1.31x	1.91x
Debt/Equity (TTM)	7.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.20	-0.05
52W Performance	-71.9%	8.2%
YTD Performance	-48.3%	59.8%
% from 52W High	-75.0%	-12.9%
% from 52W Low	0.0%	73.7%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.85x
FCF Yield (TTM)	13.7%	3.4%
Earnings Yield (TTM)	-13.8%	8.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	21.0	39.7
EV/GP/RG	N/A	N/A
Ticker research	View AKBA research	View PLX research